Polaroid Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Polaroid Therapeutics is an early-stage, private biotech startup targeting the critical global health threat of antimicrobial resistance (AMR) through small molecule discovery. Founded in Zurich in 2022, the company is currently in a pre-clinical or research phase, operating with minimal public disclosure. Its mission positions it within a high-need but challenging sector of infectious disease therapeutics, where innovation is urgently required to combat drug-resistant pathogens.

Infectious Disease

Technology Platform

Undisclosed small molecule platform targeting antimicrobial resistance. Likely involves novel mechanism of action discovery, potentially leveraging computational design or virulence factor disruption.

Opportunities

The urgent global need for new antimicrobial therapies creates a significant opportunity, supported by growing push/pull incentive programs like the AMR Action Fund and potential new subscription-based payment models.

A successful novel therapy could address a critical unmet medical need and attract partnership or acquisition interest from large pharma.

Risk Factors

Extreme scientific risk in antibiotic discovery with high preclinical failure rates.

The traditional antimicrobial market has poor commercial returns, creating a 'valley of death' between approval and profitability.

As an early-stage, stealth-mode company, it faces high financial risk and dependency on future fundraising in a competitive environment.

Competitive Landscape

The competitive landscape is intense, featuring large pharmaceutical companies (e.g., Pfizer, Merck), specialized biotechs (e.g., Entasis, Venatorx), and numerous academic consortia. Success requires a truly differentiated approach to overcome scientific hurdles and navigate a challenging market structure.

More companies in Switzerland →